{"nctId":"NCT02993107","briefTitle":"PALISADE Follow-on Study (ARC004)","startDateStruct":{"date":"2016-12-29","type":"ACTUAL"},"conditions":["Peanut Allergy"],"count":388,"armGroups":[{"label":"Group 1 (Placebo Crossovers)","type":"OTHER","interventionNames":["Biological: AR101"]},{"label":"Group 2 (Active Rollovers)","type":"OTHER","interventionNames":["Biological: AR101"]}],"interventions":[{"name":"AR101","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Completion of the ARC003 study\n* Written informed consent and/or assent from subjects/guardians as appropriate\n* Use of effective birth control by sexually active female subjects of child-bearing potential\n\nKey Exclusion Criteria:\n\n* Early discontinuation from the ARC003 study\n* Meets any longitudinally applicable ARC003 study exclusion criteria\n* (Group 2 only) Failure to tolerate â‰¥ 443 mg cumulative of peanut protein with no or mild symptoms in the ARC003 study Exit DBPCFC\n* Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"55 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Ages 4-17 With Treatment-related Adverse Events (TEAE)","description":"Percentage of subjects ages 4-17 with at-least 1 TEAE, including serious adverse events, during the overall study period. The percentage of subjects reporting at least 1 TEAE by maximum reported severity is also presented using the 5-point CTCAE severity grading scale. All safety evaluations were conducted using the safety population (all subjects who received at least 1 dose of AR101 during ARC004), age 4-17 years. Safety data are presented for group 1 (former placebo) and Group 2 data are divided into columns for cohort 1 (QD), cohort 2 (overall), cohort 3A (QD), and cohorts 3B and 3C (overall).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"27","spread":null},{"groupId":"OG004","value":"28","spread":null},{"groupId":"OG005","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"13","spread":null},{"groupId":"OG005","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"15","spread":null},{"groupId":"OG005","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Ages 4-17 Responding to Each Challenge Dose at Exit DBPCFC (Double-blind, Placebo-controlled Food Challenge)","description":"The percentage of subjects who tolerated each the of 300 mg, 600 mg, 1000 mg, or 2000 mg challenge doses with no more than mild symptoms at exit DBPCFC. Analyses based on DBPCFCs used the completer population (age 4-17 years).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"98.1","spread":null},{"groupId":"OG002","value":"94.7","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"81.8","spread":null},{"groupId":"OG005","value":"90.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","spread":null},{"groupId":"OG001","value":"89.3","spread":null},{"groupId":"OG002","value":"71.1","spread":null},{"groupId":"OG003","value":"96.2","spread":null},{"groupId":"OG004","value":"77.3","spread":null},{"groupId":"OG005","value":"76.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.2","spread":null},{"groupId":"OG001","value":"80.6","spread":null},{"groupId":"OG002","value":"57.9","spread":null},{"groupId":"OG003","value":"96.2","spread":null},{"groupId":"OG004","value":"68.2","spread":null},{"groupId":"OG005","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null},{"groupId":"OG001","value":"48.5","spread":null},{"groupId":"OG002","value":"36.8","spread":null},{"groupId":"OG003","value":"80.8","spread":null},{"groupId":"OG004","value":"45.5","spread":null},{"groupId":"OG005","value":"42.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Cough","Vomiting","Abdominal pain","Urticaria","Headache"]}}}